Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| GitLab | CXMT | Moderna | |
|---|---|---|---|
| Moat rating | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. | none CXMT's 2026 interim report (published 2026-08-29) names scale and IDM technology as core competencies, but also concedes gaps. It says that compared with the leading international manufacturers the Company 'still has a certain gap in overall scale, technology accumulation and customer resources' (与国际头部厂商相比，公司在整体规模、技术积累、客户资源等方面仍然存在一定差距). It describes its scale effect as 'gradually emerging' (逐步显现), and its gross-margin risk covers the case where the scale effect cannot materialise over the long term (公司规模效应长期无法显现). Its excess returns span a single shortage. The retained-earnings note shows an accumulated deficit of ¥36.65bn entering 2026, after ¥1.87bn of 2025 net profit attributable to the parent, and the first-half 2025 net loss attributable to shareholders was ¥2.33bn. Then first-half 2026 revenue rose 873.64%, which the report attributes to the global DRAM supply shortage, higher prices and sharply higher volumes, and the main-business gross margin reached 84.84%. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." | none On the report's own evidence, no candidate moat source qualifies. Cost scale: the report calls DRAM a highly standardised product (高度标准化的产品) in which the cost advantage of scale is a core competency. But CXMT ranks fourth globally by capacity, and the report, calculating on sales, puts Samsung, SK hynix and Micron at 33.96%, 34.48% and 23.41% of the 2025 global DRAM market, so the scale advantage lies with the leaders. IP: it reports 4,484 domestic patents (3,744 of them invention patents) and 3,400 overseas patents as of 2026-06-30. Yet it describes its core technology as reaching 'international advanced level' (国际先进水平) and flags possible IP disputes with competitors. Switching costs: ¥133.48bn of ¥150.31bn first-half 2026 revenue went through distributors, who under the report's revenue note decide their own resale prices. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. | fast follower TrendForce (2026-09-24) reports that CXMT's global DRAM revenue share rose to 9.5% in 2Q26 from 7.6% in 1Q26, 'placing it fourth behind Samsung at 39.4%, SK hynix at 24.9%, and Micron at 23.3%'. It is catching up through generation-skipping R&D. The interim report had its fifth process platform in customer certification, and a voluntary disclosure on 2026-09-21 announced that platform's mass production, adding that its products are not yet in scale sales and yields need time to ramp. TrendForce's listing analysis (2026-07-28) still says CXMT 'still trails Samsung, SK hynix, and Micron in advanced processes, product performance, yields, and certification by high-end customers'. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." | weak CXMT is a price taker riding the cycle. The interim report attributes first-half revenue growth to the global DRAM supply shortage, rising prices and sharply higher volumes. It records industry prices between 2015 and 2025 as high as $7.89/GB and as low as $1.78/GB in first-half 2023, and it states that the continued steep price rise is not sustainable. Main-business revenue was ¥15.22bn against cost of ¥13.29bn in first-half 2025, and ¥150.04bn against ¥22.75bn in first-half 2026. Most sales go through distributors, who set their own resale prices. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". | CXMT (ChangXin) is a Hefei-based IDM that designs and fabricates DDR5 and LPDDR4X/LPDDR5/5X/LPDDR6 memory and sells DRAM wafers, chips and modules. Its 2026 interim report says it reached its fourth process platform through a 'generation-skipping' (跳代研发) R&D strategy, and that it ranks first in China and fourth globally by shipments and sales. First-half 2026 revenue was ¥150.31bn (DDR series ¥69.47bn, LPDDR series ¥78.19bn), with a main-business gross margin of 84.84%. TrendForce puts its 2Q26 DRAM revenue share at 9.5%, up from 7.6% in 1Q26. The position is real but recent. The report concedes gaps to the three leaders in scale, technology and customers. The customers it names are Alibaba Cloud, ByteDance, Tencent, Lenovo, Xiaomi, Transsion, Honor, OPPO and vivo. On 2026-06-08 the US Defense Department added its subsidiary ChangXin Memory to the Section 1260H list. TrendForce notes that export controls leave CXMT relying on DUV multiple patterning rather than EUV, and that its prospectus 'has not disclosed a clear mass-production timetable' for HBM. The report itself warns that the continued steep rise in DRAM prices is not sustainable (价格的持续大幅上涨不具备可持续性) as international makers add capacity. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. | Upstream DRAM IDM selling wafers, chips and modules to server, smartphone, PC and automotive makers, mostly through distributors (¥133.48bn of ¥150.31bn first-half 2026 revenue). | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |